BioLineRx has dosed the first patient with motixafortide, CXCR4 inhibitor, in the P-II (CheMo4METPANC) study, conducted in collaboration with Columbia University, for the treatment of PDAC
The P-II (CheMo4METPANC) study investigates motixafortide + cemiplimab + gemcitabine + nab-paclitaxel vs gemcitabine and nab-paclitaxel alone for treating 1L metastatic pancreatic cancer patients (n=108)
Furthermore, the results, as of Jul 2023, revealed that PRs in the pilot phase were seen in 7/11 patients of which 5 had confirmed PR during the data cut off, hepatic metastatic lesion was resolved in 1 patient & stable disease was seen in 3 patients which resulted in a DCR of 91%
Ref: BioLineRx | Image: BioLineRx
Related News:- BioLineRx’s Aphexda (motixafortide) + Filgrastim Receives the US FDA’s Approval for Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
